Epilepsy Treatment May Work Through Your Gut, Not Just Ketosis

Roughly 30% of the more than 50 million people worldwide living with epilepsy never achieve seizure control through standard medications. For decades, the ketogenic diet has been a last-resort option for those patients, especially children, and the leading explanation for why it works has centered on one mechanism: ketosis. A narrative review published July 3, 2026 in the journal Nutrients argues that story is incomplete. The real action, the authors suggest, may run through the gut.

Gut Microbiota Alterations Found Consistently in Epilepsy Patients

Patients with epilepsy show measurable differences in gut microbial composition compared to healthy individuals. Specifically, the review describes decreased levels of Bacteroidetes and increased Actinobacteria, alongside reduced populations of Bifidobacterium and Lactobacillus, the latter two of which have been associated with fewer seizure episodes in observational data. These are not random fluctuations. Disruption of the gut microbiome influences epilepsy by altering seizure susceptibility and treatment response through the microbiota-gut-brain axis (MGBA), a bidirectional communication network linking intestinal bacteria to the central nervous system via neural, endocrine, immune, and metabolic pathways.

The MGBA shapes several processes relevant to epilepsy: neuroinflammation, blood-brain barrier integrity, and the production of neurotransmitters like serotonin and gamma-aminobutyric acid (GABA). When the axis is disrupted, chronic neuroinflammation and altered neuronal excitability can follow. The review also flags an underappreciated possibility: gut bacteria may directly influence the absorption and metabolism of antiepileptic drugs, potentially explaining why some patients respond poorly even to medications that work well for others.

Drug-Resistant Epilepsy Bears a Disproportionate Burden

Understanding why this matters requires appreciating the scale of the problem. Approximately 40% of epilepsy patients are drug-resistant, facing a substantial burden of illness that conventional pharmacotherapy cannot address. For this population, ketogenic dietary therapies (KDTs), a category of high-fat, low-carbohydrate, adequate-protein diets first developed in the 1920s, represent one of the few evidence-backed alternatives, particularly in pediatric cases.

What the review adds is a richer account of how those diets might work. Inducing ketosis is only part of the picture. The authors propose that KDTs also act as powerful modulators of the MGBA, reshaping gut microbial ecology in ways that reduce neuroinflammation and alter the availability of microbial metabolites that directly affect brain excitability.

How Ketogenic Diets Reshape the Gut Microbial Landscape

The review documents specific microbial shifts that follow ketogenic dietary therapy. KDTs reduce carbohydrate-degrading bacteria and overall microbial diversity while enriching taxa including Bacteroides, Prevotella, and Akkermansia, and they suppress Escherichia coli populations. These shifts matter because the microbiota's metabolic output changes in parallel. Short-chain fatty acids (SCFAs), small molecules produced when gut bacteria ferment dietary fiber, are key intermediaries: they help regulate gut barrier integrity, modulate immune signaling, and appear to influence neuronal excitability directly.

Research in animal models has reinforced this picture. Studies using germ-free and antibiotic-treated mice found that fecal microbiota transplantation from ketogenic diet-fed donors could restore the diet's antiseizure effects in recipient animals, suggesting the microbiome is not merely a bystander but a functional mediator of the diet's benefits. The review extends this framework to other dietary approaches including the Modified Atkins Diet (MAD), the low-glycemic-index treatment (LGIT), and Mediterranean dietary patterns, each of which may modulate the MGBA through distinct but overlapping mechanisms.

Beyond dietary structure, the authors examine microbiota-targeted supplementation: probiotics, prebiotics, and postbiotics. Increases in Bifidobacterium and Lactobacillus through probiotic intervention have correlated with reduced seizure frequency, and fecal microbiota transplantation has shown early beneficial effects in some drug-resistant cases. These findings point toward a model where remodeling the gut ecosystem, through food or through direct microbial intervention, could become a component of epilepsy management.

Key Gaps in the Clinical Evidence

The enthusiasm needs tempering. This is a narrative review, not a clinical trial, and the authors are explicit about what remains unknown. Mechanistic studies in humans are sparse, and most of the microbiome data comes from small or heterogeneous cohorts. Further research is necessary to confirm preliminary findings on altering gut bacterial composition in drug-resistant epilepsy, and no published studies have yet examined prebiotic supplementation specifically for this condition. The clinical data for probiotics and postbiotics in epilepsy remain limited enough that no treatment recommendations can be derived from current evidence.

The review also does not resolve a fundamental question of directionality: does epilepsy cause gut dysbiosis, or does dysbiosis worsen seizure susceptibility, or both? Answering that question will require longitudinal studies tracking gut microbiota composition before and after seizure onset, ideally in well-characterized patient cohorts.

Microbiota-Based Strategies as the Next Frontier in Seizure Management

Despite those caveats, the review makes a conceptually important argument: dietary therapies for epilepsy should be understood as modulators of the microbiota-gut-brain axis and neuroimmune homeostasis, not simply as metabolic interventions. That framing opens new therapeutic territory. Emerging microbiota-based therapeutic strategies, including approaches that combine gut microbiota modulation with antiseizure medications, are already being proposed as a way to reach patients for whom current options fall short.

The practical implication for researchers is that future trials of ketogenic diets and dietary supplements in epilepsy should measure gut microbial composition and SCFA profiles alongside seizure frequency. Without that data, it will be impossible to know which component of a dietary intervention is doing the work. For patients and clinicians, the message is more cautious: the gut-brain connection in epilepsy is real and increasingly well-characterized, but the evidence base for microbiota-targeted treatments remains early-stage. Established dietary therapies like the ketogenic diet retain their evidence base; the question now is how much more they may be doing than anyone previously realized.

Evidence rating

EMERGING — 75/100

Caveats:

• This is a narrative review, not an original clinical trial — it synthesizes existing studies rather than generating new data.
• Most underlying studies are small or preclinical; the direct causal link between specific microbial shifts and seizure reduction in humans has not been established.
• Probiotic and prebiotic data for epilepsy remain limited and have not been replicated at scale.
• Funding was not disclosed in the available record; independent replication of key claims is still needed.

Narrative review synthesizing clinical and experimental literature on gut microbiota, dietary therapies, and epilepsy. As a non-systematic review it cannot establish causation, and the underlying primary studies vary widely in design and sample size. Key mechanistic claims — particularly around SCFAs and specific taxa — are plausible and consistent with broader gut–brain axis literature but have not been independently replicated in large controlled human trials.

References

1. Valentina Biagioli, Mariarosaria Matera, Ilaria Imola, et al. (2026). Beyond Ketosis: Dietary Therapies and the Microbiota–Gut–Brain Axis in Epilepsy. Nutrients. https://doi.org/10.3390/nu18132151
2. Epilepsy and the Microbiome: From Mechanisms to Potential Therapies. frontiersin.org. https://www.frontiersin.org/articles/10.3389/fneur.2024.1352721/full
3. The burden of epilepsy and unmet need in people with focal seizures – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10330058/
4. Mi Tang, Wei Wang, Jiwen Wang, Yingyan Wang (2025). Alteration of Gut Microbiota by Ketogenic Diet as an Alternative Therapeutic Target for Drug-Resistant Epilepsy. Microorganisms. https://doi.org/10.3390/microorganisms13112539
5. The gut microbiome in drug‐resistant epilepsy – PMC – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10950394/
6. Barbara Federici, Giovanni Battista Dell’Isola, Pasquale Striano, Alberto Verrotti (2025). Intestinal microbiome and epilepsy: a new therapeutic approach?. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2025.2550724